Intelligence Feed event · Equity · 2026-09-01

    Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials

    Question

    Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials

    Direct answer

    Novartis announced top-line Phase III data from its REMODEL-1 and REMODEL-2 trials evaluating remibrutinib in patients with relapsing multiple sclerosis. The oral Bruton's tyrosine kinase (BTK) inhibitor met primary endpoints by reducing annualized relapse rates with statistical superiority over teriflunomide. The results establish remibrutinib as a key growth asset within Novartis's immunology and neurology portfolio, with filing submissions expected to follow based on its combined efficacy and tolerability profile.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials”, revision 1, evidence through 2026-09-01. https://marketontology.com/market-events/2026-09-01/novartis-btk-inhibitor-remibrutinib-succeeds-in-phase-iii-ms-trials-ecba26

    EQUITY
    Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials
    Novartis announced top-line Phase III data from its REMODEL-1 and REMODEL-2 trials evaluating remibrutinib in patients with relapsing multiple sclerosis. The oral Bruton's tyrosine kinase (BTK) inhibitor met primary endpoints by reducing annualized relapse rates with statistical superiority over teriflunomide. The results establish remibrutinib as a key growth asset within Novartis's immunology and neurology portfolio, with filing submissions expected to follow based on its combined efficacy and tolerability profile.
    NVS
    Impact
    73
    SEP 1
    SIG
    90%
    NVS
    Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials
    Novartis announced top-line Phase III data from its REMODEL-1 and REMODEL-2 trials evaluating remibrutinib in patients with relapsing multiple sclerosis. The oral Bruton's tyrosine kinase (BTK) inhibitor met primary endpoints by reducing annualized relapse rates with statistical superiority over teriflunomide. The results establish remibrutinib as a key growth asset within Novartis's immunology and neurology portfolio, with filing submissions expected to follow based on its combined efficacy and tolerability profile.
    → Positive Phase III superiority data over active comparator teriflunomide positions remibrutinib for global regulatory filings, expanding Novartis's commercial neuro-immunology pipeline.
    Impact
    Novartis announced top-line Phase III data from its REMODEL-1 and REMODEL-2 trials evaluating remibrutinib in patients with relapsing multiple sclerosis. The oral Bruton's tyrosine kinase (BTK) inhibitor met primary endpoints by reducing annualized relapse rates with statistical superiority over teriflunomide. The results establish remibrutinib as a key growth asset within Novartis's immunology and neurology portfolio, with filing submissions expected to follow based on its combined efficacy and tolerability profile.
    Affected
    NVS
    Transmission
    Positive Phase III superiority data over active comparator teriflunomide positions remibrutinib for global regulatory filings, expanding Novartis's commercial neuro-immunology pipeline.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    NVScommercial pipeline expansion via Phase III BTK inhibitor superiorityUp1-4wNovartis announced positive Phase III REMODEL-1/-2 trial results for remibrutinib in RMS.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month